CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction Classification of Deaths in Cardiovascular Outcomes Trials Known Unknowns and Unknown Unknowns Shock Team Approach in Refractory Cardiogenic Shock Requiring Short-Term Mechanical Circulatory Support: A Proof of Concept Acute Noncardiac Organ Failure in Acute Myocardial Infarction With Cardiogenic Shock Management of two major complications in the cardiac catheterisation laboratory: the no-reflow phenomenon and coronary perforations 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR)

Clinical Trial2020 Nov 7;41(42):4114-4123.

JOURNAL:Eur Heart J. Article Link

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial

J Tuñón, PG Steg, ODYSSEY OUTCOMES Investigators et al. Keywords: chronic kidney disease; glomerular filtration rate; Low-density lipoprotein cholesterol; MACE; PCSK9 inhibition

Full Text PDF